<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03978494</url>
  </required_header>
  <id_info>
    <org_study_id>1829-TAC-1</org_study_id>
    <secondary_id>2018-002672-40</secondary_id>
    <nct_id>NCT03978494</nct_id>
  </id_info>
  <brief_title>Study to Compare Pharmacokinetics of Tacrolimus Prolonged-release (PR) Capsules and Advagraf® PR Capsules in Stable Kidney Transplant Patients.</brief_title>
  <acronym>TODAY</acronym>
  <official_title>Randomized, Multicenter, Open-Label, Two-period, Two-sequence Crossover Comparative Pharmacokinetic Study of Generic Tacrolimus (Sandoz) and Advagraf® in Stable Renal Transplant Patients (TODAY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sandoz</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sandoz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to compare pharmacokinetics of tacrolimus prolonged-release (PR) capsules and Advagraf®
      PR capsules in stable kidney transplant patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Initially, patients will enter a short screening period, and those who continue to meet the
      inclusion and exclusion criteria will be randomized to receive either test or reference
      medicinal product in Period 1. In period 2 they will switch to the other formulation. During
      the whole treatment period four full-pharmacokinetics profiles will be established.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    company decision
  </why_stopped>
  <start_date type="Anticipated">September 2, 2019</start_date>
  <completion_date type="Anticipated">May 3, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 3, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC(0-τ)ss</measure>
    <time_frame>Day 21 of each treatment period</time_frame>
    <description>Area under the whole blood concentration curve during a dosage interval (τ=24 hours) at steady state</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss</measure>
    <time_frame>Day 21 of each treatment period</time_frame>
    <description>Maximum whole blood concentration at steady state</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC(0-τ)ss</measure>
    <time_frame>Day 14 of each treatment period</time_frame>
    <description>Area under the whole blood concentration curve during a dosage interval (τ=24 hours) at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss</measure>
    <time_frame>Day 14 of each treatment period</time_frame>
    <description>Maximum whole blood concentration at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss</measure>
    <time_frame>Days 14 and 21 of each treatment period</time_frame>
    <description>Minimum whole blood concentration at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cτ,ss</measure>
    <time_frame>Days 14 and 21 of each treatment period</time_frame>
    <description>Concentration at the end of the dosing interval at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cav</measure>
    <time_frame>Days 14 and 21 of each treatment period</time_frame>
    <description>Average concentration during a dosing interval: AUC(0-τ)/τ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss</measure>
    <time_frame>Days 14 and 21 of each treatment period</time_frame>
    <description>Time to reach maximum (peak) plasma concentration at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-τ)ss coefficient of variation</measure>
    <time_frame>Days 14 and 21 of each treatment period</time_frame>
    <description>Intra-patient pharmacokinetics variability evaluated by calculating AUC(0-τ)ss coefficient of variation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss coefficient of variation</measure>
    <time_frame>Days 14 and 21 of each treatment period</time_frame>
    <description>Intra-patient pharmacokinetics variability evaluated by calculating Cmax,ss coefficient of variation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% Fluctuation</measure>
    <time_frame>Days 14 and 21 of each treatment period</time_frame>
    <description>Degree of fluctuation of the analyte concentration levels over one dosing interval: 100*(Cmax,ss − Cmin,ss)/Cav.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%Swing</measure>
    <time_frame>Days 14 and 21 of each treatment period</time_frame>
    <description>Degree of change of the analyte concentration levels over one dosing interval: 100*(Cmax,ss - Cτ,ss)/Cτ,ss.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Kidney Transplant</condition>
  <arm_group>
    <arm_group_label>Period 1: Advagraf®; Period 2: Generic tacrolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Period 1 patients will receive branded tacrolimus (Advagraf®) orally once-a-day and in Period 2 patients will receive the generic tacrolimus (Sandoz) orally once-a-day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 1: Generic tacrolimus; Period 2: Advagraf®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Period 1 patients will receive the generic tacrolimus (Sandoz) orally once-a-day and in Period 2 patients will receive branded tacrolimus (Advagraf®) orally once-a-day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Advagraf®</intervention_name>
    <description>Advagraf®1 mg and 5 mg prolonged-release hard capsules once daily (reference medicinal product).</description>
    <arm_group_label>Period 1: Advagraf®; Period 2: Generic tacrolimus</arm_group_label>
    <arm_group_label>Period 1: Generic tacrolimus; Period 2: Advagraf®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Generic tacrolimus</intervention_name>
    <description>Tacrolimus 1 mg and 5 mg prolonged release hard capsules (Sandoz) once daily (test medicinal product)</description>
    <arm_group_label>Period 1: Advagraf®; Period 2: Generic tacrolimus</arm_group_label>
    <arm_group_label>Period 1: Generic tacrolimus; Period 2: Advagraf®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients aged ≥18 years;

          -  Patients with a Body Mass Index (BMI) included in the interval [18.5-33.0] kg/m²;

          -  Patients who received a primary kidney transplant at least 12 months prior to study
             entry

        Exclusion Criteria:

          -  Evidence or suspicion of ongoing or persistent, acute or chronic rejection;

          -  Requirement for dialysis within the six months prior to study entry;

          -  Glomerular filtration rate (GFR) &lt;30 mL/min

          -  Pregnant or breastfeeding women, confirmed by a positive human chorionic gonadotropin
             (hCG) laboratory test;

          -  Intolerance to tacrolimus, excipients (including lactose, fructose or galactose), or
             similar products;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandoz</last_name>
    <role>Study Director</role>
    <affiliation>Sandoz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Suresnes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Kaiserslautern</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandoz Investigative Site</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 5, 2019</study_first_submitted>
  <study_first_submitted_qc>June 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2019</study_first_posted>
  <last_update_submitted>September 12, 2019</last_update_submitted>
  <last_update_submitted_qc>September 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney transplant; Renal transplant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

